Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03186378 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Systemic Exposure to VP-102 in Subjects With Molluscum Contagiosum.
A Phase 2 study, sponsored by Verrica Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
NCT03186378 is a Phase 2 study that has completed, run by Verrica Pharmaceuticals. The registered enrollment target is 33 participants.
The verdict
NCT03186378, a Phase 2 study, has completed, sponsored by Verrica Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
Study Summary
The primary objective of the study is to determine the presence or absence of systemic cantharidin exposure from a single 24-hour dermal application of VP-102 topical film-forming solution \[0.7% (w/v) cantharidin\] (VP-102) when applied to molluscum contagiosum (molluscum) lesions on pediatric subjects 2 years old and older. Treatment will continue over the course of 3 additional 21 day intervals allowing for further evaluation of safety, efficacy and impact on quality of life.
Interventions
- COMBINATION_PRODUCT VP-102 with applicator
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2017-06-08 |
| Est. Completion | 2018-06-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03186378
The ClinicalTrials.gov registry entry for NCT03186378 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Verrica Pharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which VP-102 with applicator is the first listed.
NCT03186378 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03186378 about?
NCT03186378 is a clinical study titled "Evaluation of Systemic Exposure to VP-102 in Subjects With Molluscum Contagiosum.". The primary objective of the study is to determine the presence or absence of systemic cantharidin exposure from a single 24-hour dermal application of VP-102 topical film-forming solution \[0.7% (w/v) cantharidin\] (VP-102) when applied to molluscum contagiosum (molluscum) lesions on pediatric subj...
What is the current status of trial NCT03186378?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2017-06-08. Estimated completion is 2018-06-25.
What interventions are being tested in trial NCT03186378?
The interventions under investigation include: VP-102 with applicator (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03186378?
This trial is sponsored by Verrica Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.